Showing results (231-240 of 317) with videos related to
Sort By:
Pageof 32
Pediatric Blood & Cancer|April 6, 2011
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology GroupMartin A Champagne, Cecilia H Fu, Myron Chang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology groupPhoenix A Ho, Julia Kuhn, Robert B Gerbing, et al.Blood Advances|December 7, 2020
Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology GroupKaren M Chisholm, Amy E Heerema-McKenney, John K Choi, et al.Proteomics. Clinical Applications|June 8, 2023
Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology GroupFieke W Hoff, Yihua Qiu, Brandon D Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy AugmentationAbdelrahman H Elsayed, Xueyuan Cao, Amit K Mitra, et al.Pediatric Blood & Cancer|March 12, 2015
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology GroupTamara P Miller, Andrea B Troxel, Yimei Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531Alan S Gamis, Todd A Alonzo, Soheil Meshinchi, et al.Pediatric Blood & Cancer|May 7, 2015
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology GroupKelly D Getz, Yimei Li, Todd A Alonzo, et al.Blood Advances|January 23, 2023
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemiaRichard J Marrero, Xueyuan Cao, Huiyun Wu, et al.JAMA Oncology|November 11, 2021
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 TrialMatthew A Kutny, Todd A Alonzo, Oussama Abla, et al.Pageof 32